Roche’s Post

🩺 Rise in Lymphoma Cases in India: A Call for Early Diagnosis & Treatment As lymphoma cases continue to rise in India, the importance of early detection and timely treatment cannot be overstated. This article highlights the growing concern and discusses critical advancements in cancer treatment. From insights into diagnostic challenges to innovative therapeutic approaches, this is a must-read for healthcare professionals and those committed to better cancer care outcomes. 🔗 Read more about it here: Sushmita Panda Sakshi Kuchroo Sumana Sarkar Syed Fazal Bari Roshun Povaiah E Kumar Sharma Roche Lymphoma Research Foundation #Healthcare #CancerAwareness #Lymphoma #EarlyDiagnosis #MedicalResearch #PatientCare

Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management Good interesting updated review

Want to learn more about how you can enhance your clinical trial experience for your patients? Read below on how we have supported a Phase III Mantle Cell Lymphoma trial. mdgroup #clinicaltrials #clinicalresearch #patientaccess

PICC-related venous thrombosis in patients with lymphoma - Full Text... "The objective of this study is to examine the risk factors associated with the occurrence of PICC-Related Venous Thrombosis (PICC-RVTE) in individuals diagnosed with lymphoma, as well as to develop a predictive risk nomogram model" Wang et al (2024).

PICC-related venous thrombosis in patients with lymphoma - Full Text... "The objective of this study is to examine the risk factors associated with the occurrence of PICC-Related Venous Thrombosis (PICC-RVTE) in individuals diagnosed with lymphoma, as well as to develop a predictive risk nomogram model" Wang et al (2024).

The second study of my PhD has now been published 😊 Earlier this year, I had to opportunity to present my work at the annual meeting of the Danish lymphoma group. It was notably presented as “ … the study that caused the most discussion by co-authors ever” (or something along those lines). In this study, we tested the potential effectiveness of R-CHOEP over R-CHOP in young patients with high-risk DLBCL. After we balanced confounders, we could not confirm superiority of R-CHOEP over R-CHOP and the use of these intensive therapies should be carefully evaluated for each patient. If you want to read it you can find it here:  https://lnkd.in/dEW4KawD

🌟 Exciting Developments in Hodgkin's Lymphoma Treatment 🌟 Here is some encouraging news for those affected by Hodgkin's lymphoma. Recent advances in treatment are bringing new hope and possibilities for patients and their families. Innovative therapies, including targeted treatments and immunotherapies, are showing remarkable results in improving survival rates and quality of life. These breakthroughs are a testament to the power of research, collaboration, and dedication in the medical field. As the world continues to make strides in understanding and combating this disease, let's take a moment to recognize the resilience of those battling Hodgkin's lymphoma and the tireless efforts of healthcare professionals and researchers. Together, we are moving closer to a future where Hodgkin's lymphoma is not just treatable but curable. Let's keep pushing the boundaries of what's possible! #HealthcareInnovation #LymphomaAwareness #MedicalResearch #HopeForACure #SMO #SCLAManagemnt Read more about these strides in combating this disease: https://lnkd.in/gGM3gXjJ

Lymphoma Treatment | Hodgkins Lymphoma (HL) | Non Hodgkins Lymphoma (NHL) | Dr Karuna Kumar Lymphomas, encompassing Hodgkin's Lymphoma (HL) and Non-Hodgkin's Lymphoma (NHL), present a diverse landscape in hematologic cancers. This exploration delves into the evolving strategies for lymphoma treatment, offering insights into the distinctive approaches for HL and NHL. From targeted therapies to immunotherapies, join us as we navigate the dynamic field of lymphoma treatment, shedding light on the ongoing efforts to tailor interventions for each subtype. This discussion aims to empower individuals with a deeper understanding of the complexities surrounding lymphoma and the promising avenues for effective treatment. . . . . #LymphomaTreatment #HodgkinsLymphoma #NonHodgkinsLymphoma #HematologicCancers #CancerTreatmentStrategies #LymphomaInsights #TargetedTherapies #ImmunotherapyOptions #CancerResearch #TailoredInterventions #HLandNHL

Big news in the fight against lymphoma! Bristol Myers Squibb's persistence pays off as Breyanzi carves a new path in mantle cell lymphoma treatment ✅ After initial triumphs with Breyanzi, continual efforts for expansion have borne fruit yet again. For those battling relapsed or refractory mantle cell lymphoma (MCL), the landscape just changed. With a fresh FDA stamp of approval, Breyanzi now steps up as the first CAR-T cell therapy sanctioned for four non-Hodgkin lymphoma subtypes 💊 This approval doesn't just mark a milestone; it's a beacon of hope for MCL patients who've braved multiple treatments, including BTK inhibitors, without success. Imagine, 85% of those treated with Breyanzi witnessed a response, with 68% achieving complete responses. And for many, these results weren't fleeting - they held strong for at least a year with just a one-time infusion 💉 Bristol Myers Squibb isn't stopping at approvals. They are scaling up, ensuring production keeps pace with hope, ready to meet the rising demand.Let's celebrate this advance and the promise it holds 🎉 #Breyanzi #BristolMyersSquibb #CARTtherapy #MantleCellLymphoma #ClinicalResearch #ClinicalTrials #LifeScience #ElixirAssociates #StaffingPartner

Proud to share with you our latest review on microRNAs with relevance to classical Hodgkin lymphoma pathogenesis. #lymphomaresearchgroningen (https://lnkd.in/edNXQitd)